Dr. Suparno Chakrabarti in Delhi: Fees, Timing, Reviews | Narayana Health

Dr. Suparno Chakrabarti

MD, FRCPATH Senior consultant & HOD

  • SpecialityBone Marrow Transplant (Stem Cell Transplant), Haemato Oncology, Oncology

  • HospitalDelhi - Dharamshila Narayana Superspeciality Hospital


Warning message

The subscription service is currently unavailable. Please try again later.

Narayana Health » Delhi » Bone Marrow Transplant Stem Cell Transplant Haemato Oncology Oncology » Dr Suparno Chakrabarti

Brief Profile

Suparno Chakrabarti is the Head of the Dept for Blood and Marrow Transplantation and Hematology at Dharamshila Narayana Hospital and Research Centre, New Delhi, India. He initiated the first Haploidentical BMT program in India and along with Dr Sarita Jaiswal has developed this as a sustained alternate donor program with over 125 Haploidentical transplants in the past 7 years. They have innovated newer methods of carrying out haploidentical BMT in patients with advanced leukemia as well as aplastic anemia with excellent results. His key area of research is Transplant immunology in relation to Haploidentical BMT.
Dr Chakrabarti trained in Internal Medicine at PGIMER, Chandigarh in India. Subsequently, he spent 12 years in the UK, initially as a research fellow and subsequently as a consultant in the field of BMT. During this period, he played a substantial role in developing Campath-1H based T cell depletion and reduced intensity conditioning. The bulk of his research also focussed on post-transplant virus infections and immune reconstitution. He has over 100 publications to his credit.
He has established a world-class BMT centre in the country and runs a charitable organisation for children with blood diseases.

Key areas of Research

    Haploidentical HSCT; NK cell Biology; Post-transplantation Immune reconstitution; Transplantation tolerance. The following are the academic highlights:
  • Peer reviewer for several scientific journals including BLOOD, Bone Marrow Transplantation, Haematologica, British Journal of Haematology, Clinical Infectious Diseases, Biology of Blood and Marrow Transplantation, JAMA, Lancet etc.
  • Reviewer of grant proposals for AIRC (The Italian Association for the Search on the Cancer).
  • Invited speaker at Asia-Pacific BMT Congress2002, Asian Transplant Congress, 2002, & EBMT workshop Milan, 2004 etc.
  • Editorial Board member for ‘several journals.
  • Expert panel member on post-transplant infections of the Centre for International Bone marrow Transplant Registry, USA (2008).
  • Invited Guest Editor for several journals on special issues on Transplantation.

Key Publications

  • Chakrabarti S, Singh K, Singh V, Nain CK, Jindal SK. Airway response to acid instillation in esophagus in bronchial asthma. Indian J Gastroenterol 1995; 14(2): 44-47.
  • Chakrabarti S, Behera D, Varma S, Bambery P. Methyl prednisolone in sarcoidosis associated thrombocytopenia. Sarcoidosis 1997; 14: 188.
  • Chakrabarti S, Varma S, Singh S, Kumari S. Low dose amino caproic acid : an alternative to platelet transfusion in thrombocytopenia. European Journal of Haematology 1998; 60(5): 313-314.
  • Chakrabarti S, Varma S, Kochhar R, Rajwanshi A, Gupta S.Hepatosplenic tuberculosis: a cause for persistent fever in recovering neutropenia. Int. J. Tuberculosis and Lung Dis 1998; 2(7):575-579.
  • Chakrabarti A; Varma N; Kumar B; Chakrabarti S; Varma S. Dyskeratosis congenita: DNA repair defect ?. Indian Journal of Hematology and Blood Transfusion. 1998 Mar.; 16(1): 34-7
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW: Fulminant adenvirus hepatitis following unrelated donor bone marrow transplant: failure of ribairin therapy. Bone Marrow Transplant 1999; 23: 1209-1211.
  • Chakrabarti S, Collingham K, R H Stevens, Fegan CD, Milligan DW: Isolation of viruses from stools in stem cell transplant recipients. Bone Marrow Transplant 2000; 25; 277-282.
  • Chakrabarti S, Pillay D, Ratcliffe D, Cane P, Collingham K, Milligan DW: Herpes Simplex Virus Infections in stem cell transplant recipients: significance of antiviral resistance and its prognostic significance. Journal of Infectious Disease 2000; 181: 2055-2058.
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW. Adenovirus infections following stem cell transplantation: is there a role for adoptive immunotherapy. Bone Marrow Transplant 2000; 26(3): 305-307.
  • Kottaridis PD, Milligan D W, Chopra R, Chakraverty RK, Chakrabarti S et al. In vivo Campath 1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 2000; 96(7): 2419-25.
  • Chakrabarti S, Lees A, Jones S, Milligan DW. Clostridium difficile infection in stem cell transplant recipients is associated with severe graft versus host disease and non-relapse mortality. Bone Marrow Transplant 2000;26:871-876.
  • Chakrabarti S, Collingham K, Pillay D, Holder K, Milligan DW. Parainfluenza virus infection after BMT: response to ribavirin. Clin Infectious Disease 2000;26:1516-1518 .
  • Chakrabarti S, Handa S, Bryon RJ, Grifiths M, Milligan DW. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant. Transplantation 2001; 72: 340-342.
  • Chakrabarti S, Alsop A, Sepphard S et al. Establishment of a community-based autologous blood stem cell service in UK: a pilot study. British Journal of Intensive Care 2001; 11: 51-56.
  • Robertson JD, Testa NG, Russell NH, Jackson G, Parker AN, Milligan DW, Stainer C, Chakrabarti S, Dougal M and Chopra R. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant 20001; 27: 1283-1286.
  • Chakrabarti S, McDonald D, Milligan DW. T cell depleted nonmyeloablative transplantation: What is the optimum balance between the intensity of host-conditioning and degree of T cell depletion? (letter).Bone Marrow Transplant 2001: 28; 313-314.
  • Chakrabarti S, Collingham K, Fegan CD, Milligan DW. Respiratory viral infections in adult T cell depleted stem cell transplants: the role of cellular immunity. Transplantation 2001; 72: 1460-63.
  • Chakraverty R, PeggsK, Chopra R, Milligan D, Kottaridis P, Verfuerth P, Geary J, Thuraisundaram D, Branson K, Chakrabarti Set all.
  • Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2001;99: 1071-78.
  • Chakrabarti S, Collingham K E, Holder K, Fegan CD, Osman H, Milligan D W Pre-emptive therapy of paramyxovirus infections after haematopoetic stem cell transplantation with oral ribavirin: a pilot study. Bone Marrow Transplant 2001;28:759-763.
  • Milligan D, Chakrabarti S. Parainfluenza virus infections in stem cell transplant recipients. In Respiratory Virus infections; Not just a snuffly nose, October, 2001 (pub: eurocommunications).
  • Chakrabarti S, Collingham K E, Fegan CD, Osman H, Milligan D W. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001;28:759-763.
  • Kottaridis PD, Milligan D W, Chopra R, Chakraverty RK, Chakrabarti S et al. In vivo Campath 1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Cytotherapy 2001; 3:197-201.
  • Chakrabarti S. Critical factors in optimising graft-versus-leukaemia effect for relapsed acute leukemia (letter). Journal Clin Oncol 2002; 20:2756
  • Chakrabarti S. The place of rituximab in the treatment algorithm of post-SCT auto-immune hemolytic anemia. Haematologica 2002; 87 (ELT 2
  • Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of CMV reactivation after nonmyeloablative transplants: potential role of CAMPATH-1H in delayed immune recovery. Blood 2002; 99: 4357-63.
  • Chakrabarti S et al. Adenovirus infections in Stem cell transplant recipients: the incidence and outcome in relation to graft manipulation, immunosuppression and immune reconstitution. Blood 2002; 100: 1619-1627.
  • Rymes NL, Lester W, Connor C, Chakrabarti S, Fegan CD. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haematol 2002; 24:165-170.
  • Chakrabarti S et al. Respiratory Virus Infections In Transplant Recipients After Reduced Intensity Conditioning With CAMPATH-1H: High Incidence But Low Mortality. British Journal of Haematology 2002;119: 1125-32
  • Chakrabarti S. Non-herpes viral infections and anti-viral immunity after stem cell transplantation. Transplant proceedings 2002; 35: 509-510
  • Chakrabarti S. The relevance of nonmyeloablative transplantation in developing countries: the lessons from the UK experience. Transplant proceedings 2002; 35: 172-173
  • Chakrabarti S Increased CMV Infection Following Nonmyeloablative Allogeneic Stem Cell Transplantation: A Search For The Guilty. Blood (letter) 2003: 101; 2071.
  • Cane P, van der Hoogan BG, Chakrabarti S, Fegan C, Osterhaus AD. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003 Feb;31(4):309-10
  • Chakrabarti S et al. Polyoma viruria in stem cell transplant recipients T cell depleted with Campath-1H: the incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003 Mar;31(5):379-86
  • Chakrabarti S, MacDonald M, Hale G et al. T cell depletion with Campath-1H in the bag for matched related peripheral stem cell transplantation is associated with low incidence of GVHD, rapid immune recovery and improved survival. British Journal of Haematology 2003 Apr;121(1):109-18
  • Chakrabarti S et al,. Early Lymphocyte Recovery Is An Important Determinant Of Outcome Following Allogeneic Transplantation with CD34+ Selected Graft And Limited T Cell Addback. Bone Marrow Transplantation 2003; 32: 23-30.
  • Chakrabarti S, Milligan D, Pillay D. Reconstitution of Epstein-Barr-Virus-Specific Cytotoxic T Lymphocyte Response Following T-Cell Depleted Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation. Blood 2003 Aug 1;102(3):839-42
  • Chakrabarti S, Marks DI. Should we T cell deplete sibling grafts for AML in CR-1 (Review). Bone Marrow Transplant. 2003;32(11):1039-50.
  • Chakrabarti S, Mautner V et al. Adenovirus infections in stem cell transplant recipients (invited review). Leuk Lymphoma 2004; 45: 873-885.
  • Chakrabarti S et al. Influence Of Cytomegalovirus (CMV) Sero-Positivity On CMV Infection, Lymphocyte Recovery And Non-CMV Infections Following T Cell Depleted Allogeneic Stem Cell Transplantation:A Comparison Between Two T Cell Depletion Regimens. Bone Marrow Transplantation Bone Marrow Transplant. 2004;33(2):197-204.
  • Chakrabarti S and Bareford D. Will The Developments In Allogeneic Transplantation Influence Management Of Adult Patients With Sickle Cell Disease? (Review)Biology of Blood and Marrow Transplantation Biol Blood Marrow Transplant. 2004 Jan;10(1):23-31.
  • Chakrabarti S, Osman H, Collingham K et al. Enterovirus infections following T-cell depleted Allogeneic transplantation in adults. Bone Marrow Transplant. 2004 Feb;33(4):425-30
  • Avivi I, Chakrabarti S et al. Incidence and outcome of adenovirus disease following alemtuzumab-based reduced intensity allogeneic transplantation. Biology of Blood and Marrow Transplantation. 2004 Mar;10(3):186-94.
  • Lahteenmaki PM, Chakrabarti S et al. Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen.Acta Oncol. 2004;43(2):196-203.
  • Avivi I, Chakrabarti S et al. Neurological complications following alemtuzumab-based reduced intensity allogeneic transplantation. Bone Marrow Transplantation 2004 ; 34(2):137-42
  • Chakrabarti S, Hale G, Waldmann H. Alemtuzumab in allogeneic stem cell transplantation: where do we go from here. Tranplant Proceedings. 2004; 36:1225-7.
  • Karanth M, Chakrabarti S et al. A Randomised Study Comparing Peripheral Blood Progenitor Mobilisation Using Intermediate Dose Cyclophosphamide Plus Lenograstim With Lenograstim Alone. Bone Marrow Transplantation 2004; 34: 399-403.
  • Aleem A, Lovell R, Holder K, Chakrabarti S et al. Performing bone marrow harvest on an outpatient basis: a single center UK experience. Acta Haematol. 2004;112(4):200-2.
  • Chakrabarti S. Alemtuzumab in-vivo or in-vitro: the impact on infections, relapse and immune reconstitution. Proceedings of the 3rd workshop of EBMT, October, 2004.
  • Cohen J, Cooper N, Chakrabarti S et al. EBV-related disease following hematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma (invited review).
  • Chakrabarti S. Nonmyeloablative Allogeneic Stem Cell Transplantation: Achievements, Failures And The Future. Current Stem cell Research (invited review).
  • Chakrabarti S and Bareford D. A Survey on Patients' Perception of Reduced Intensity Transplantation in Adults with Sickle Cell Disease. Bone Marrow Transplant. Bone Marrow Transplantation 2007; 39: 447 - 451.
  • Chakrabarti S. Bone Marrow Transplantation: a potential cure neglected? News Review of Sickle Cell Society, Spring 2007.
  • Chakrabarti S. Adenovirus infections after hematopoietic stem cell transplantation: still unravelling the story. Clin Infect Dis 2007; 45(8):966-968. (Editorial Commentary)
  • Anoop P, Bevan DH, Chakrabarti S. Usefulness and limitations of Bayesian network model as a mortality risk assessment tool in sickle cell anemia. Am J Hematol. 2009 May;84(5):312-3.
  • Buyck HC, Holliman R, Else J, O'Regan L, Willis F, Grubnic S, Marsh J, Chakrabarti S. An unusual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited.. Bone Marrow Transplant. 2008 Jun;41(12):1069-70.
  • Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant. 2009 May;43(10):813-6
  • Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention.Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):471-82
  • Chakrabarti S. Prevention and Treatment of Hepatitis virus infections in Hematopoietic StemCell Transplant Recipients. Medit J Hemat Infect Dis 2009, 1: DOI 10.4084/MJHID.2009.
  • Chakrabarti S. How do you treat secondary Iron Overload? Disorders of Iron Homeostasis. 2010. Edited by Ghosh MK et al. Chapter 20.
  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.
  • Chakrabarti S. Thalassemia in Developing World: care or Cure. Annals of Inst of Child Health, 2010; 10 (1): 12-17.
  • Chakrabarti S. When matched family donor is not available for blood and marrow transplantation- the Indian dilemma. Apollo Medicine, 2012;9: 62-67.
  • Jaiswal S et al. Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. BBMT. 2013; 19:S346
  • Jaiswal S et al. Persistently High GAM Levels Are Associated with Nonrelapse Mortality in HCT Recipients Irrespective of Invasive Aspergillosis: A Prospective Cohort Study. . BBMT. 2013; 19:S264
  • Jaiswal S et al. Second Haploidentical PBSC Transplantation From the Same Donor After Early Relapse without Gvhd in Patients with Acute Leukemia. BBMT. 2013; 19:S264.
  • Jaiswal S et al. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? Leukemia & Lymphoma Jun 2013, Vol. 54, No. S1: 3–31
  • Jaiswal S. NK Alloreactive Donor Is Associated With Reduced Relapse In Refractory AML But High Nonrelpase Mortality In Patients With Aplastic Anemia Following T-Replete Haploidentical PBSCT With Post Transplant. HEMATOLOGICA; 2013: 98 (S1); 159
  • Jaiswal S, Chatterjee S, Chakrabarti S. Paternal Bone Marrow Infusion As Salvage Therapy For Severe Gvhd Following Maternal Haploidentical Transplantation Resulting In Biparental Chimersim. Int J Hematol, 2013; Oct;98(4):504-8. doi: 10.1007/s12185-013-1426-5.
  • Jaiswal S et al. Pretransplant Sirolimus Might Improve The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. Bone Marrow Transplant, 2015; 50: 873-875; advance online publication, March 23, 2015; doi:10.1038/bmt.2015.50
  • Chakrabarti A, Jaiswal S, Chakrbarti S. Sirolimus As Long-Term Graft-Versus-Host-Disease Prophylaxis In Haploidentical Hematopoietic Stem Cell Transplant Recipients For Non-Malignant Disorders Is Associated With High Incidence Of Acneiform Lesions. Indian Journal of Dermatology, Year : 2015 | Volume: 60 | Issue Number: 6 | Page: 588-591.
  • Jaiswal S et al. Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. International Journal of Hematology 11/2015; DOI:10.1007/s12185-015-1905-y.
  • Jaiswal S et al. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with a Fludarabine, Busulfan and Melphalan Based Conditioning. Biology of blood and marrow transplantation: 11/2015; DOI:10.1016/j.bbmt.2015.11.010
  • Jaiswal S et al. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia. Blood: 2015; 126 (23).
  • Jaiswal S et al. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia. Blood: 2015; 126 (23)
  • Jaiswal SR, Chakrabarti S. Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Adv.Hematol. 2016; 2016: 3467672
  • Jaiswal SR. Haploidentical Transplantation in Children with Unmanipulated PBSC Graft in Children: The Need to Look Beyond Post-Transplantation Cyclophosphamide In Younger Children. Ped Transplant. 2016. 20; 675–682.
  • Jaiswal SR, Chakrabarti S. Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemia: Early Hype or Sustained Enthusiasm. Clinics in Oncology. 2016; in press.
  • Jaiswal S et al. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia Following Post-Transplantation Cyclophosphamide Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic GCSF-Mobilized Donor Lymphocyte Infusions. Biol Blood Marrow Transplant. 2016 Jul 25. pii: S1083-8791(16)30252-X. doi: 10.1016/j.bbmt.2016.07.016. [Epub ahead of print]
  • Jaiswal S et al. T Cell Costimulation Blockade For Hyperacute Steroid Refractory Graft Versus-Host Disease In Children Undergoing Haploidentical Transplantation. Transplant Immunol. 10.1016/j.trim.2016.08.009.
  • Jaiswal S et al. CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide for Haploidentical Transplantation of Advanced Myeloid Malignancies Is Associated With Prompt Reconstitution of Mature Natural Killer Cells and Regulatory T Cells with Reduced Incidence of Acute Graft Versus Host Disease: A Pilot Study. Cytotherapy (2017; in press).
  • Jaiswal S et al. Gut Colonization with Carbapenem Resistant Enterobactriaceae (CRE) Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of a Prospective Surveillance Study. Blood 128, no. 22 (2016): 2402. Accessed January 18, 2017. www.bloodjournal.org/content/128/22/2402.
  • Jaiswal SR, Bhakuni P, Zaman S, Bansal S, Bharadwaj P, Bhargava S et al. T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia. Transpl. Immunol. 2017.
  • Jaiswal, S. R., Bhakuni, P., Bharadwaj, P., Zaman, S., & Chakrabarti, S. (2017).CTLA4Ig Primed Donor Lymphocyte Infusions (DLI): A Novel Approach to Natural Killer Cell Immunotherapy Following Haploidentical PBSC Transplantation for Advanced Hematological Malignancies. Blood, 130 (Suppl 1), 4468. www.bloodjournal.org/content/130/Suppl_1/4468
  • Jaiswal, SR et al. Jaiswal, SR et al. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor–Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell–Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study. Biology of Blood and Marrow Transplantation 2018 Mar;24(3):542-548.
  • Chakrabarti S, O’Donnell PV, Reissner Y, Aversa F. Haploidentical Family Donor Transplantation: At the Crossroads of a Changing Paradigm. Advances in Hematology. Volume 2016 (2016), Article ID 9753542, 2 pages. dx.doi.org/10.1155/2016/9753542
  • Yanamandra U. Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. Indian J Hematol Blood Transfus. 2017 Mar;33(1):15-21. doi: 10.1007/s12288-016-0773-9
  • Jaiswal SR et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study. Mediterr J Hematol Infect Dis. 2018 May 1;10(1):e2018025. doi: 10.4084/MJHID.2018.025.
  • Jaiswal SR et al. Higher CD45RA+ Regulatory T Cells in The Graft Improves Outcome in Younger Patients Undergoing T Cell Replete Haploidentical Transplantation: Where Donor Age Matters. Biology of Blood and Marrow Transplantation, 2018: 24; 2025-2033.
  • Jaiswal SR, Bhakuni P, Joy A, Kaushal S, Chakrabarti A, Chakrabarti S CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. Biol Blood Marrow Transplant. 2019 Apr;25(4):673-682. doi: 10.1016/j.bbmt.2018.12.836. Epub 2019 Jan 2.
  • Jaiswal SR, Bhakuni P, Bhagwati G, Joy A, Chakrabarti A, Chakrabarti S.Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1621-1628. doi: 10.1016/j.bbmt.2019.04.023. Epub 2019 May 22.
  • Jaiswal SR, Bhakuni P, Bhagawati G, Chakrabarti A, Chakrabarti S. CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following post-transplantation cyclophosphamide-based haploidentical transplantation. Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0549-6. [Epub ahead of print]
  • Jaiswal SR, Bhakuni P, Bansal S, Aiyer HM, Bhargava S, Chakrabarti S. Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e430-e435. doi: 10.1016/j.clml.2019.04.008. Epub 2019 Apr 30.
  • Jaiswal SR, Chakrabarti S. Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet! Indian J Hematol Blood Transfus. 2019 Jul;35(3):416-422. doi: 10.1007/s12288-019-01077-x. Epub 2019 Jan 23. Review.
  • Jaiswal SR, Aiyer HM, Rawat G, Gera A, Chakrabarti S. CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study. Exp Hematol. 2019 Aug 23. pii: S0301-472X(19)30945-2. doi: 10.1016/j.exphem.2019.08.002. [Epub ahead of print]
  • Jaiswal SR, Bhakuni P, Chakrabarti A, Chakrabarti S. Rotavirus infection following post-transplantation cyclophosphamide based haploidentical hematopoietic cell transplantation in children is associated with hemophagocytic syndrome and high mortality. Transpl Infect Dis. 2019 Jun 28:e13136. doi: 10.1111/tid.13136. [Epub ahead of print]
  • Jaiswal SR, Bhakuni P, Bhagwati G, Aiyar HM, Chakrabarti A, Chakrabarti S. Alterations In NKG2A and NKG2C Subsets Of Natural Killer Cells following Epstein Barr Virus Reactivation In CTLA4Ig Based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.Transplantation. 2019 Aug 29. doi: 10.1097/TP.0000000000002941. [Epub ahead of print]
  • Jaiswal SR, Chakrabarti S. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation. Immunotherapy. 2019 Sep 3. doi: 10.2217/imt-2019-0037. [Epub ahead of print]